Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) target, is demonstrating promising data in preliminary patient studies. Ongoing examination https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/